Embolization-on-a-chip: Novel Vascularized Liver Tumor Model for Evaluation of Cellular and Cytokine Response to Embolic Agents DOI Creative Commons
Huu Tuan Nguyen, Zuzana Tirpáková, Arne Peirsman

и другие.

bioRxiv (Cold Spring Harbor Laboratory), Год журнала: 2025, Номер unknown

Опубликована: Апрель 4, 2025

ABSTRACT Background Embolization is a well-established treatment modality for liver cancer. However, traditional embolization agents are limited by inefficient delivery and aggregation in blood vessels. Novel shear-thinning hydrogels (STH) have been developed to address the need safer more effective local of embolic therapeutics. Objective We aim evaluate efficacy novel such as STH using human-relevant vitro model that recapitulates human hepatocellular carcinoma capillary networks. Methods A vascularized liver-tumor-on-a-chip was assess agent performance. The effects drug-eluting (DESTH) on tumor cell viability, surface marker expression, vasculature morphology, cytokine responses were evaluated. To study microvasculature morphology independent chemotherapy compound, we assessed effect different drug-free vascular microenvironment under flow conditions. Results DESTH induced death, downregulated expression Epithelial Cell Adhesion Molecules (EpCAM) HepG2, increased levels cytokines Interleukin-4 (IL-4), Granulocyte-macrophage colony-stimulating factor (GM-CSF), Vascular Endothelial Growth Factor (VEGF), decreased albumin secretion. Furthermore, exert distinct microvascular with causing complete regression Conclusion This tumor-on-a-chip enables human-relevant, real-time assessment response, paving way development innovative therapies

Язык: Английский

Embolization-on-a-chip: Novel Vascularized Liver Tumor Model for Evaluation of Cellular and Cytokine Response to Embolic Agents DOI Creative Commons
Huu Tuan Nguyen, Zuzana Tirpáková, Arne Peirsman

и другие.

bioRxiv (Cold Spring Harbor Laboratory), Год журнала: 2025, Номер unknown

Опубликована: Апрель 4, 2025

ABSTRACT Background Embolization is a well-established treatment modality for liver cancer. However, traditional embolization agents are limited by inefficient delivery and aggregation in blood vessels. Novel shear-thinning hydrogels (STH) have been developed to address the need safer more effective local of embolic therapeutics. Objective We aim evaluate efficacy novel such as STH using human-relevant vitro model that recapitulates human hepatocellular carcinoma capillary networks. Methods A vascularized liver-tumor-on-a-chip was assess agent performance. The effects drug-eluting (DESTH) on tumor cell viability, surface marker expression, vasculature morphology, cytokine responses were evaluated. To study microvasculature morphology independent chemotherapy compound, we assessed effect different drug-free vascular microenvironment under flow conditions. Results DESTH induced death, downregulated expression Epithelial Cell Adhesion Molecules (EpCAM) HepG2, increased levels cytokines Interleukin-4 (IL-4), Granulocyte-macrophage colony-stimulating factor (GM-CSF), Vascular Endothelial Growth Factor (VEGF), decreased albumin secretion. Furthermore, exert distinct microvascular with causing complete regression Conclusion This tumor-on-a-chip enables human-relevant, real-time assessment response, paving way development innovative therapies

Язык: Английский

Процитировано

0